Tolerable and curable treatment in HIV/HCV co-infected patients using anti-HCV direct antiviral agents: a real-world observation in China

Li, Yuanyuan; Li, Linghua; Li, Jun; Zhang, Dawei; Zhao, Fang; Wang, Li; Mahemure, Aizezi; Xie, Rong-hui; Lei, Suyun; Cai, Weiping; Wang, Xicheng; Shu, Zhanjun; Chen, Xiejie; Wang, Hui; Wang, Fusheng

doi:10.1007/s12072-018-9891-9

Cited by 13 publications

(8 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our study, similarly to previous studies, demonstrated the efficacy of DAAs in the treatment of several sub-populations of HCV-infected individuals (HBV or HIV co-infections and solid organ transplant recipients) (Li et al, 2018;Zhang et al, 2019). Therefore, we suggest that HCV eradication with DAA regimens should not be withheld in these populations as all had excellent results.…”

Section: A B Csupporting

confidence: 88%

Efficacy and Safety of Direct-Acting Antiviral Therapy in Patients With Chronic Hepatitis C Virus Infection: A Real-World Single-Center Experience in Tianjin, China

Xia

Wang

et al. 2020

Front. Pharmacol.

View full text Add to dashboard Cite

Objective: Toward the limited real-world data concerning the treatment response to brand direct-acting antiviral agents (DAAs) therapy, we proposed to evaluate the efficacy and safety of DAAs for the treatment of chronic hepatitis C virus (HCV) in mainland China. Methods: In this retrospective, single-center, cohort study, all HCV-infected adult patients treated with brand DAA drugs covered by Tianjin local health insurance (Apr 2018-Sept 2019) and responding to other specific inclusion criteria were recruited. The five available DAA regimens included sofosbuvir + ribavirin (SOF + RBV), elbasvir/ grazoprevir (EBR/GZR), ombitasvir/paritaprevir/ritonavir/dasabuvir (OBV/PTV/r/DSV) ± RBV, daclatasvir + asunaprevir (DCV + ASV), and SOF + DCV ± RBV. Demographic, virologic, clinical, and adverse effects data obtained during and after DAAs treatment were collected. We evaluated the rate of sustained virological response at 12 weeks posttreatment (SVR12), the incidence of adverse effects, and assessed the factors associated with SVR12. Results: Four hundred ninety-four patients finished the treatment and completed the 12week post-treatment follow-up. The overall SVR12 rate was estimated at 96.96%. SVR rates greater than 95% were achieved in most of the HCV genotypes with the exception of GT1a (0%), GT3a (93.33%), and GT3b (88.24%). SVR12 for patients treated with DCV + ASV, EBR/GZR, OBV/PTV/r/DSV ± RBV, SOF + DCV ± RBV, and SOF + RBV for 12 or 24 weeks was 86.67%, 100%, 98.11%, 97.56%, and 95.06%, respectively. Subjects with compensated cirrhosis (92.73%) and prior treatment experience (77.78%) had significantly lower SVR rates when compared to chronic hepatitis C (98.15%) and treatment-naive (97.69%) groups. In Tianjin, the available DAA regimens were generally well-tolerated, and not a single serious adverse event was reported.

show abstract

Section: A B Csupporting

confidence: 88%

Efficacy and Safety of Direct-Acting Antiviral Therapy in Patients With Chronic Hepatitis C Virus Infection: A Real-World Single-Center Experience in Tianjin, China

Xia

Wang

et al. 2020

Front. Pharmacol.

View full text Add to dashboard Cite

show abstract

“…The available DAA regimens were generally well-tolerated and with high efficiency in the treatment of HIV/HCV co-infected patients, with similar efficacy to those with mono HCV infection. There was no significant difference in adverse effects among patients with different baseline CD4 + T-cell count in those who received DAA regimens with or without Peg-IFN and RBV [34].…”

Section: Discussionmentioning

confidence: 84%

Transmission networks of hepatitis C virus among HIV/HCV-coinfected patients in Guangdong, China

Deng

Liang

Cai

et al. 2022

Virol J

Self Cite

View full text Add to dashboard Cite

Background Coinfection with hepatitis C virus (HCV) is common in human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS) patients due to shared routes of transmission. We aimed to investigate the characteristics of HCV subgenotypes among HIV/HCV-coinfected patients in Guangdong and explore the molecular transmission networks and related risk factors for HCV strains. Methods Plasma samples were obtained from 356 HIV/HCV-coinfected patients for HCV NS5B region sequencing. A neighbor-joining phylogenetic tree was constructed to affirm HCV subgenotypes. The transmission networks based on maximum likelihood phylogenetic tree were determined by Cluster Picker, and visualized using Cytoscape 3.2.1. Results A total of 302 HCV NS5B sequences were successfully amplified and sequenced from the 356 plasma samples. A neighbor-joining phylogenetic tree based on the 302 NS5B sequences revealed the profile of HCV subgenotypes circulating among HIV/HCV coinfection patients in Guangdong. Two predominant strains were found to be 6a (58.28%, 176/302) and 1b (18.54%, 56/302), followed by 3a (10.93%, 33/302), 3b (6.95%, 21/302), 1a (3.64%, 11/302), 2a (0.99%, 3/302) and 6n (0.66%, 2/302). A molecular transmission network of five major HCV genotypes was constructed, with a clustering rate of 44.04%. The clustering rates of subgenotypes 1a, 3a, 3b, 1b, and 6a were 18.18% (2/11), 42.42%, 52.38%, 48.21%, and 44.89%, respectively. Multivariate logistic regression analysis showed no significant effects from sex, age, transmission route, geographical region, baseline CD4 + T cell count or subgenotype (P > 0.05), except marital status. Married or cohabiting people (compared with unmarried people) had more difficulty forming transmission networks. Conclusions In summary, this study, based on HCV NS5B subgenotypes, revealed the HCV subtype diversity and distribution among HIV/HCV-coinfected patients in Guangdong. Marital status inclined to be the factor influencing HCV transmission networks formation.

show abstract

“…Multiple trials and real-world studies have been carried out to investigate the efficacy and safety of DAAs in HIV–HCV coinfected patients. DAAs are demonstrated to result in SVR rates comparable to that in HCV mono-infection settings 9 and real-world evidence further corroborated these findings 10 , 11 . Therefore, treatment against active HCV infection defined as detection of HCV RNA is now generally recommended for all HCV patients regardless of HIV infection status.…”

Section: Introductionmentioning

confidence: 63%

Sofosbuvir plus Ribavirin is effective for HCV elimination in people living with HIV from rural area of China

Chen

Kang

et al. 2021

Sci Rep

View full text Add to dashboard Cite

People living with HIV (PLWH) bear higher prevalence of HCV coinfection. An accessible directly acting antivirals regimen with less drug–drug interaction with antiretroviral therapy (ART) is urgently needed in source limited regions. We aimed to assess the efficacy and safety of SOF + RBV for 24 weeks regimen in HIV–HCV coinfected patients in Liangshan Prefecture, China. PLWH under ART from China’s national free antiretroviral treatment project (CNFATP) and diagnosed with treatment-naïve HCV infection were enrolled. SOF + RBV was administrated for 24 weeks and patients were followed for ≥ 12 weeks. The efficacy and safety were analyzed and related factors were explored. 58 patients completed 24 weeks of SOF + RBV and had all tests done. Genotype prevalence in this population was G3 44.8% (n = 26), G6 31.0% (n = 18) and G1 17.2% (n = 10) respectively. 52/58 (89.7%) patients achieved SVR12 while 10.3% experienced therapeutic failure. However, SVR12 was neither significantly different between groups of different gender, age, transmission routines, CD4+ cell count, HIV infection duration, ART duration and HBsAg prevalence nor influenced by HCV viral load, genotypes and hepatic stiffness. The regimen was well-tolerated without any serious AEs or AEs leading to treatment adjustment or discontinuation reported. PLWH in Liangshan showed a high prevalence of HCV coinfection with GT3 and GT6 as the most frequent genotypes. SOF + RBV for 24 weeks could achieve good SVR12 in this population and was well-tolerated. It has great potential to be generalized in coinfected population in source-limited regions.

show abstract

Tolerable and curable treatment in HIV/HCV co-infected patients using anti-HCV direct antiviral agents: a real-world observation in China

Abstract: We showed generic SOF + DCV and SOF + LDV regimens were well tolerated and with high efficiency. Patient's baseline CD4 T-cell count did not exhibit significant difference in adverse effects.

Cited by 13 publications

References 24 publications

Efficacy and Safety of Direct-Acting Antiviral Therapy in Patients With Chronic Hepatitis C Virus Infection: A Real-World Single-Center Experience in Tianjin, China

Efficacy and Safety of Direct-Acting Antiviral Therapy in Patients With Chronic Hepatitis C Virus Infection: A Real-World Single-Center Experience in Tianjin, China

Transmission networks of hepatitis C virus among HIV/HCV-coinfected patients in Guangdong, China

Sofosbuvir plus Ribavirin is effective for HCV elimination in people living with HIV from rural area of China

Contact Info

Product

Resources

About